Russia plans to continue imports of high-priced Western drugs after 2020

13 November 2015

The Russian government has officially announced that the share of domestic drugs in the domestic pharmaceutical market will reach 90% in volume terms by 2018, reports The Pharma Letter’s local correspondent.

This is expected to be achieved in the case of successful implementation of Pharma 2020, a state program, aimed at replacing of drug imports in the Russian pharmaceutical market until 2020.

According to an official spokesman of the Russian Ministry of Health, since the launch of the Pharma 2020 program the volume of investments in the Russian pharmaceutical industry has amounted to 120 billion roubles ($1.85 billion), of which 39 billion roubles were allocated from the state sources.

Since 2012 more than a dozen pharmaceutical plants have been put into operation in Russia, with about 30 enterprises being subject to modernization. The most successful pharmaceutical technoparks are currently located in Yaroslavl, Kaluga and Moscow regions. In the Moscow region the share of domestic drugs could reach 70% as soon as 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK